LEWISVILLE, Texas--(BUSINESS WIRE)--
Orthofix International (NASDAQ: OFIX) announces the full market release
of Collage™ Osteoconductive Scaffold, a new bone graft
substitute, for use in spine and orthopedic indications, at this week's
North American Spine Society (NASS) meeting to be held in Chicago,
Illinois.
"We are proud to announce the launch of Collage, our new synthetic
platform based on highly-purified biocompatible materials of ß-TCP and
type-1 collagen," said Michael Finegan, President of Biologics. "We have
been tremendously successful with Trinity Evolution and can now focus on
broadening our portfolio of biologic products so that we can fulfill all
the needs of our customers. The synthetic segment of the market is
large, attractive, and presents a perfect complement to our existing
biologic portfolio."
The U.S. market for synthetic bone graft substitutes is estimated to
include more than 320,000 procedures and is valued at approximately $360
million annually, according to a recent iData Research report.
About Orthofix
Orthofix International N.V. is a global medical device company offering
a broad line of minimally invasive surgical, and non-surgical products
for the spine, orthopedics, and sports medicine market sectors that
address the lifelong bone-and-joint health needs of patients of all ages
helping them achieve a more active and mobile lifestyle. Orthofix's
products are widely distributed around the world to orthopedic surgeons
and patients via Orthofix's sales representatives and its subsidiaries,
including BREG, Inc., and via collaborations with other leading
orthopedic product companies. In addition, Orthofix is collaborating on
R&D activities with leading research and clinical organizations such as
the Musculoskeletal Transplant Foundation, the Orthopedic Research and
Education Foundation, Texas Scottish Rite Hospital for Children, and the
Cleveland Clinical Foundation. For more information about Orthofix,
please visit http://www.orthofix.com.
Orthofix International N.V.
Mark Quick, 214-937-2924
Director
of Investor Relations and Business Development
markquick@orthofix.com
Source: Orthofix International N.V.
News Provided by Acquire Media